These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 24018887)

  • 21. Diagnostic and therapeutic utility of monoclonal antibodies in urologic oncology.
    McCarley DL; Weiner RS
    Semin Surg Oncol; 1989; 5(4):293-301. PubMed ID: 2672236
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extracellular microRNAs in urologic malignancies: chances and challenges.
    Huang X; Liang M; Dittmar R; Wang L
    Int J Mol Sci; 2013 Jul; 14(7):14785-99. PubMed ID: 23863690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The translational potential of microRNAs as biofluid markers of urological tumours.
    Fendler A; Stephan C; Yousef GM; Kristiansen G; Jung K
    Nat Rev Urol; 2016 Dec; 13(12):734-752. PubMed ID: 27804986
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Molecular diagnostics in urologic oncology. Detection of nucleic acids in urine samples].
    Müller M; Goessl C; Krause H; Miller K
    Urologe A; 2003 May; 42(5):660-8. PubMed ID: 12750801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The application of immunohistochemical biomarkers in urologic surgical pathology.
    Wilkerson ML; Lin F; Liu H; Cheng L
    Arch Pathol Lab Med; 2014 Dec; 138(12):1643-65. PubMed ID: 25427043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker, Molecular, and Technologic Advances in Urologic Pathology, Oncology, and Imaging.
    Ellis CL; Harik LR; Cohen C; Osunkoya AO
    Arch Pathol Lab Med; 2017 Apr; 141(4):499-516. PubMed ID: 28157406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SH3BGRL3 Protein as a Potential Prognostic Biomarker for Urothelial Carcinoma: A Novel Binding Partner of Epidermal Growth Factor Receptor.
    Chiang CY; Pan CC; Chang HY; Lai MD; Tzai TS; Tsai YS; Ling P; Liu HS; Lee BF; Cheng HL; Ho CL; Chen SH; Chow NH
    Clin Cancer Res; 2015 Dec; 21(24):5601-11. PubMed ID: 26286913
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nucleic acid-based tissue biomarkers of urologic malignancies.
    Dietrich D; Meller S; Uhl B; Ralla B; Stephan C; Jung K; Ellinger J; Kristiansen G
    Crit Rev Clin Lab Sci; 2014 Aug; 51(4):173-99. PubMed ID: 24878394
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C-reactive protein in urologic cancers.
    Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
    Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection and isolation of circulating tumor cells in urologic cancers: a review.
    Loberg RD; Fridman Y; Pienta BA; Keller ET; McCauley LK; Taichman RS; Pienta KJ
    Neoplasia; 2004; 6(4):302-9. PubMed ID: 15256052
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reduced expression of GATA3 predicts progression in non-muscle invasive urothelial carcinoma of the urinary bladder.
    Kamel NA; Abdelzaher E; Elgebaly O; Ibrahim SA
    J Histotechnol; 2020 Mar; 43(1):21-28. PubMed ID: 31551051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.
    Urquidi V; Rosser CJ; Goodison S
    Curr Med Chem; 2012; 19(22):3653-63. PubMed ID: 22680923
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Upper urinary tract urothelial carcinoma and its variants: transition from morphology to personalized molecular characterization in diagnosis, prognosis, and therapy.
    Cimadamore A; Scarpelli M; Santoni M; Cheng L; Lopez-Beltran A; Montironi R
    Expert Rev Mol Diagn; 2018 Dec; 18(12):1021-1028. PubMed ID: 30452305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary-exosomal miR-2909: A novel pathognomonic trait of prostate cancer severity.
    Wani S; Kaul D; Mavuduru RS; Kakkar N; Bhatia A
    J Biotechnol; 2017 Oct; 259():135-139. PubMed ID: 28764970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal Cell and Urothelial Carcinoma: Biomarkers for New Treatments.
    Schmidt AL; Siefker-Radtke A; McConkey D; McGregor B
    Am Soc Clin Oncol Educ Book; 2020 Mar; 40():1-11. PubMed ID: 32379987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular markers in the diagnostics and therapy of urothelial cancer].
    Protzel C; Hakenberg OW
    Urologe A; 2010 Nov; 49(11):1415-24. PubMed ID: 20959953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of snail in upper urinary tract urothelial carcinoma: prognostic significance and implications for tumor invasion.
    Kosaka T; Kikuchi E; Mikami S; Miyajima A; Shirotake S; Ishida M; Okada Y; Oya M
    Clin Cancer Res; 2010 Dec; 16(23):5814-23. PubMed ID: 20947514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma].
    Campedel L; Seisen T; Cussenot O; Comperat E; Varinot J; Rouprêt M; Cancel-Tassin G
    Prog Urol; 2018 Dec; 28(16):900-905. PubMed ID: 30219646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting vasculature in urologic tumors: mechanistic and therapeutic significance.
    Sakamoto S; Ryan AJ; Kyprianou N
    J Cell Biochem; 2008 Feb; 103(3):691-708. PubMed ID: 17668426
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet?
    Netto GJ
    Nat Rev Urol; 2011 Dec; 9(1):41-51. PubMed ID: 22158597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.